Cosmos Health Enters New Nanotechnology R&D Program to Develop Next-Generation Nutraceutical Formulas with Enhanced Phytochemical Efficacy
Cosmos Health (NASDAQ:COSM) announced a new nanotechnology R&D program launched on October 31, 2025 to develop plant-based extract-loaded phytosomes for dietary supplements.
The program builds on the company’s CCX Hydrogel platform and aims to improve absorption, stability, and bioactivity of phytochemicals using a sustainable, solvent-free process suitable for nutraceutical formulation. Company leaders described the work as an effort to deliver next-generation, scientifically driven supplements with validated functional performance.
Cosmos Health (NASDAQ:COSM) ha annunciato un nuovo programma di ricerca e sviluppo sulla nanotecnologia lanciato il 31 ottobre 2025 per sviluppare phytosome caricate di estratti vegetali per integratori alimentari.
Il programma si basa sulla piattaforma CCX Hydrogel dell'azienda e mira a migliorare l'assorbimento, la stabilità e l'attività biologica dei fitochimici utilizzando un processo sostenibile senza solventi, adatto alla formulazione nutraceutica.
I dirigenti dell'azienda hanno descritto il lavoro come uno sforzo per offrire integratori di nuova generazione, guidati dalla scienza, con prestazioni funzionali validate.
Cosmos Health (NASDAQ:COSM) anunció un nuevo programa de I+D en nanotecnología lanzado el 31 de octubre de 2025 para desarrollar fitosomas cargados de extractos vegetales para suplementos dietéticos.
El programa se apoya en la plataforma CCX Hydrogel de la empresa y tiene como objetivo mejorar la absorción, la estabilidad y la bioactividad de los fitoquímicos utilizando un proceso sostenible sin disolventes, adecuado para la formulación nutracéutica.
Los líderes de la empresa describieron el trabajo como un esfuerzo para ofrecer suplementos de próxima generación, impulsados por la ciencia, con un rendimiento funcional validado.
Cosmos Health (NASDAQ:COSM)가 2025년 10월 31일에 시작된 새로운 나노기술 연구개발 프로그램을 발표했습니다. 이는 식물성 보충제를 위한 추출물 로드된 피토좀을 개발하기 위한 것입니다.
이 프로그램은 회사의 CCX Hydrogel 플랫폼을 기반으로 피토케미컬의 흡수, 안정성 및 생체활성을 개선하는 것을 목표로 하며, 지속 가능한 용매 없는 공정을 통해 뉴트라슈티컬 제형에 적합합니다.
회사의 경영진은 이 작업을 과학적으로 주도하는 차세대 보충제를 제공하려는 노력으로 설명했고, 검증된 기능적 성과를 가진다고 말했습니다.
Cosmos Health (NASDAQ:COSM) a annoncé un nouveau programme de recherche et développement en nanotechnologie lancé le 31 octobre 2025 pour développer des phytosomes chargés d'extraits végétaux à base de plantes pour les compléments alimentaires.
Le programme s'appuie sur la plateforme CCX Hydrogel de l'entreprise et vise à améliorer l'absorption, la stabilité et la bioactivité des phytochimiques en utilisant un procédé durable sans solvants, adapté à la formulation nutraceutique.
Les dirigeants de l'entreprise ont décrit ce travail comme un effort pour proposer des compléments de nouvelle génération, scientifiquement guidés, avec des performances fonctionnelles validées.
Cosmos Health (NASDAQ:COSM) kündigte ein neues Forschungs- und Entwicklungsprogramm für Nanotechnologie an, das am 31. Oktober 2025 gestartet wurde, um pflanzenbasierte extraktgeladene Phytosomen für Nahrungsergänzungsmittel zu entwickeln.
Das Programm baut auf der CCX Hydrogel-Plattform des Unternehmens auf und zielt darauf ab, die Absorption, Stabilität und Bioaktivität von Phytochemikalien mittels eines nachhaltigen, lösungsmittelfreien Verfahrens zu verbessern, das sich für die Formulierung von Nutraceuticals eignet.
Die Unternehmensführung beschrieb die Arbeit als Bestreben, erstklassige, wissenschaftlich gestützte Ergänzungsmittel mit validierter funktionaler Leistung zu liefern.
Cosmos Health (NASDAQ:COSM) أعلنت عن برنامج بحث وتطوير في تكنولوجيا النانو جديد أُطلق في 31 أكتوبر 2025 لتطوير فايتيـوسومات محمّلة بمستخلصات نباتية لمكملات غذائية.
يعتمد البرنامج على منصة CCX Hydrogel التابعة للشركة ويهدف إلى تحسين امتصاص واستقرار ونشاط بيولوجي للمركبات النباتية باستخدام عملية مستدامة وخالية من المذيبات مناسبة لتكوين المكملات الغذائية.
وصف قادة الشركة العمل بأنه جهد لتقديم مكملات من الجيل التالي مدفوعة بالعلم وبأداء وظيفي معتمد.
- None.
- None.
Insights
Cosmos Health initiated a nanotech R&D program to create plant extract-loaded phytosomes for dietary supplements on
Bold work on nanostructured phytosomes aims to improve absorption, stability and bioactivity of phytochemicals using a solvent-free, sustainable process. The company links this effort to its existing CCX Hydrogel delivery know-how and frames the program as an upgrade to its nutraceutical pipeline.
The technical path depends on demonstrable bioavailability gains and reproducible stability data at scale; early claims require peer-reviewed or internal validation to move from lab to claimable product benefits. Key items to watch include quantified bioavailability or efficacy metrics, stability results from the cited Nanoparticle Tracking Analysis, and any timelines for external validation or regulatory clearances within the next 6–24 months.
CHICAGO, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced the initiation of a new research and development program leveraging nanotechnology to enhance the effectiveness of phytochemical constituents used in its dietary supplement formulas.
This new initiative builds upon the proprietary know-how developed during the creation of CCX Hydrogel, a breakthrough platform for optimised bioactive delivery. The Company is now expanding its innovation pipeline by developing plant-based extract-loaded phytosomes intended for use in dietary supplements. These nanostructured systems are designed to significantly improve the absorption, stability, and bioactivity of phytochemicals, leading to measurable efficacy improvements.
The approach follows a sustainable, solvent-free process, emphasising environmentally responsible, green formation of phytosomes that are fully suitable for incorporation into nutraceutical applications. This aligns with Cosmos Health’s broader commitment to sustainable innovation, scientific advancement, and responsible manufacturing.
Figure: Stability assessment of the produced phytosomes using Nanoparticle Tracking Analysis.
Greg Siokas, CEO of Cosmos Health, stated: “Our platform represents a promising step toward the development of sustainable, bioactive-enriched food technologies. By combining nanotechnology with advanced phytochemical formulations, we aim to deliver next-generation dietary supplements with validated functional performance and enhanced consumer benefits.”
Dr Panagiotis Zoumpoulakis, Head of Research & Development at Cosmos Health, added: “The integration of nanotechnology into our R&D strategy enables us to explore the full potential of phytochemicals at the molecular level. Through precise nanoscale engineering, we can optimise how these bioactive compounds are absorbed and interact within the body, resulting in superior effectiveness and consistency. This marks a significant advancement in our pursuit of scientifically driven nutraceutical innovation.”
About Cosmos Health Inc.
Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, www.cloudscreen.gr, as well as LinkedIn and X.
Forward-Looking Statements
With the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans,” and similar expressions, or future or conditional verbs such as “will,” “should,” “would,” “may,” and “could,” generally identify forward-looking statements, although not all forward-looking statements contain these words. These statements involve risks and uncertainties that may individually or materially affect the matters discussed herein for a variety of reasons outside the Company’s control, including, but not limited to: the Company’s ability to raise sufficient financing to implement its business plan; the effectiveness of its digital asset strategies, including accumulation and yield-generating activities; the impact of the war in Ukraine on the Company’s business, operations, and the economy in general; and the Company’s ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results could differ materially from those anticipated. Readers are encouraged to review the risk factors set forth in the Company’s filings with the SEC, which are available at the SEC’s website (www.sec.gov). The Company disclaims any obligation to update or revise forward-looking statements, whether as a result of new information, future events, or otherwise
Investor Relations Contact:
BDG Communications
cosm@bdgcommunications.com
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/b1d0d0db-c193-4646-afde-136e62431eb8
FAQ
What did Cosmos Health (COSM) announce on October 31, 2025 about nanotechnology R&D?
How does Cosmos Health plan to improve supplement efficacy with phytosomes?
Will Cosmos Health use solvents in the new phytosome production process?
Is the new Cosmos Health program based on existing technology?
What investor impact should shareholders expect from Cosmos Health's R&D program (COSM)?
Where did Cosmos Health describe the stability assessment of the produced phytosomes?
